LETRASAN

LETRASAN is a pharmaceutical product containing 2.5 mg of Letrozole per tablet, primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women.

Therapeutic Indications:

• Adjuvant Treatment: LETRASAN is indicated for postmenopausal women with hormone receptor-positive invasive early breast cancer, serving as an additional therapy following primary treatment to reduce the risk of cancer recurrence.
• Extended Adjuvant Treatment: It is also used for extended adjuvant treatment in postmenopausal women who have completed standard adjuvant tamoxifen therapy for five years, providing continued suppression of estrogen production to prevent cancer relapse.
• First-line Treatment: LETRASAN serves as a first-line treatment for postmenopausal women with hormone-dependent advanced breast cancer, inhibiting tumor growth by reducing estrogen levels.
• Neoadjuvant Treatment: In cases where chemotherapy is not suitable, LETRASAN is used as a neoadjuvant treatment in postmenopausal women with hormone receptor-positive, HER-2 negative breast cancer, aiding in tumor reduction before surgery.

Dosage and Administration:

The recommended dosage of LETRASAN is 2.5 mg once daily. In the adjuvant and extended adjuvant settings, treatment should continue for five years or until tumor relapse occurs. For advanced or metastatic breast cancer, treatment should persist until tumor progression is evident. LETRASAN can be taken with or without food.

Contraindications:

LETRASAN is contraindicated in individuals with hypersensitivity to Letrozole or any of its excipients. It should not be used in premenopausal women, during pregnancy, or while breastfeeding.

Special Precautions:

• Menopausal Status: Before initiating treatment, it is essential to confirm the patient’s postmenopausal status through clinical assessment and laboratory evaluations, including measurements of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol levels.
• Renal and Hepatic Impairment: Caution is advised when administering LETRASAN to patients with severe renal impairment (creatinine clearance <10 ml/min) or hepatic impairment, as these conditions may affect the drug’s metabolism and excretion.

Side Effects:

Common side effects associated with LETRASAN include hot flushes, arthralgia (joint pain), fatigue, increased sweating, and nausea. Less common but serious side effects may involve bone density reduction leading to osteoporosis, cardiovascular events, and hepatic dysfunction. Regular monitoring and supportive measures are recommended to manage these potential adverse effects.

Availability:

LETRASAN is available in 2.5 mg film-coated tablets. For purchasing information and availability, please visit ShopSteroidsOnline.com.

Conclusion:

LETRASAN (Letrozole 2.5 mg) is a critical medication in the management of hormone receptor-positive breast cancer in postmenopausal women. Its role in various treatment settings, including adjuvant, extended adjuvant, first-line, and neoadjuvant therapies, underscores its versatility and importance in oncology. Healthcare providers should assess individual patient factors, including menopausal status and organ function, to ensure the safe and effective use of LETRASAN. For more detailed information, consulting the product’s summary of characteristics and professional medical advice is recommended.